Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Tuesday that the US Patent and Trademark Office has confirmed it will grant a patent for a pharmaceutical formulation of tasquinimod on 2 December 2025, under patent number 12,485,095.

The formulation is designed for high oral bioavailability.

This patent provides protection and market exclusivity for tasquinimod in the United States until 2042. It is part of Active Biotech's strategy to strengthen global multi-layer patent protection for tasquinimod.

Tasquinimod is an orally active small molecule immunomodulator that blocks tumour-supporting pathways in the bone marrow microenvironment and is being developed for haematological malignancies. The compound has previously been studied in solid cancers, including a phase III trial in metastatic prostate cancer, and has demonstrated therapeutic potential in preclinical models of multiple myeloma and myelofibrosis.

Tasquinimod has FDA orphan drug designation for the treatment of myelofibrosis and multiple myeloma, and clinical proof-of-concept studies are ongoing in Europe and the United States.